| Jonathan Fortes Ang, MD | |
|
One Hospital Dr, Columbia, MO 65212-0001 | |
| (573) 882-8788 | |
| (573) 882-3131 |
| Full Name | Jonathan Fortes Ang |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 16 Years |
| Location | One Hospital Dr, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780956862 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
A new study in which researchers rapidly screened more than 11,000 bioactive molecules for activity against an antibiotic-resistant strain of Klebsiella pneumoniae bacteria identified multiple compounds with potent antimicrobial activity.
In today's headlines, reports about the ever-growing US health health care tab and about the petition filed by a conservative legal center to bring their health law challenge to the Supreme Court.
› Verified 7 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
A new study in which researchers rapidly screened more than 11,000 bioactive molecules for activity against an antibiotic-resistant strain of Klebsiella pneumoniae bacteria identified multiple compounds with potent antimicrobial activity.
In today's headlines, reports about the ever-growing US health health care tab and about the petition filed by a conservative legal center to bring their health law challenge to the Supreme Court.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Fortes Ang, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Jonathan Fortes Ang, MD One Hospital Dr, Columbia, MO 65212-0001 Ph: (573) 882-8788 |
News Archive
According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
A new study in which researchers rapidly screened more than 11,000 bioactive molecules for activity against an antibiotic-resistant strain of Klebsiella pneumoniae bacteria identified multiple compounds with potent antimicrobial activity.
In today's headlines, reports about the ever-growing US health health care tab and about the petition filed by a conservative legal center to bring their health law challenge to the Supreme Court.
› Verified 7 days ago
Dr. Rahul Jain, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-2296 Fax: 573-884-7743 | |
Mr. Ghulam Ghous, M.D Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Gregory Gaskey, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Christos N Papageorgiou, M.D., PHD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: One Hospital Drive, Columbia, MO 65212 Phone: 573-882-2100 Fax: 573-884-7822 | |
Jack Bragg, DO Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 S Fairview Road, Columbia, MO 65201 Phone: 573-884-7600 Fax: 573-884-8200 | |
Michelle Middleton Woodson, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 Fax: 573-814-6584 | |
Dr. Sameer Bellapravalu, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212 Phone: 573-884-6136 Fax: 573-884-1070 |